Skip to main content
OpenTrials
Completed

NCT Number: NCT02368327

Gene Expression Profiles in Muscle After Immunisation

This clinical study is part of the BIOVACSAFE project which is funded by the Innovative Medicine Initiative. In this study we will take a small muscle biopsy in order to identify any differences in the response around the actual site of injection compared with responses we measure in blood at the same time.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Surrey Clinical Research Centre

Guildford, Surrey, Gu2 7XP, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The participant is able to read and understand the Informed Consent Form (ICF), and understand study procedures.
  • The participant has signed the ICF.
  • Healthy male participants aged 18-45 years inclusive.
  • BMI between 19-27 kg/m2.
  • Pre-immunised with Hepatitis B vaccine
  • Hepatitis B sAb positive (evidence of vaccine-induced immunity)
  • Hepatitis B sAg and cAb negative (evidence of lack of prior/current HBV infection)
  • Hepatitis C and HIV seronegative.
  • Available for follow-up for the duration of the study.
  • Agree to abstain from donating blood during the study.
  • The participant is, in the opinion of the investigator, healthy on the basis of a, medical history, a symptom directed medical examination and vital signs.

Exclusion criteria

  • History of hypersensitivity to any of the vaccine components or a history of any allergy that in the opinion of the investigator would contraindicate participant participation
  • Clinically significant psychiatric, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological (particularly myasthenia gravis), immunological, or haematological disease or abnormality, as determined by the study physician.
  • Known immune or coagulation disorder or clinically significant abnormalities of platelets, Hb or coagulation on screening labs
  • Known allergy to injected local anaesthetics
  • Unwilling to undergo muscle biopsies
  • Use of steroids or immunosuppressive/immunomodulating drugs either orally or parenterally within 3 months of visit 1.
  • Currently participating in a clinical trial with an investigational or non- investigational drug or device, or has participated in another clinical trial within the 3 months preceding the study.
  • Any condition that, in the investigator's opinion, compromises the participant's ability to meet protocol requirements or to complete the study.
  • Receipt of blood products or immunoglobin, within 3 months of visit 1.
  • Unable to read and speak English to a fluency level adequate for the full comprehension of procedures required in participation and consent.

Treatment and study plan

Fluad

Biological

Fendrix

Biological

Placebo

Biological

Primary outcomes

  1. Change from baseline values of gene expression in whole blood and muscle

    Time frame: Day 0, Day 0+3 hours, Day 1, Day 3, Day 5 and Day 7

Sponsors and collaborators

Lead sponsor

University of Surrey

Other

Collaborators

  • Max Planck Institute for Infection Biology

Registry information

Official study title

Clinical Study to Generate Exploratory Training Set of Data on the Time Course of Gene Expression Profile at Site of Antigen Deposition Compared With Whole Blood Following IM Injection With Alum or MF59-adjuvanted Protein Subunit Vaccines

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Feb 23, 2015
Registry last updated
Aug 10, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.